Bone morphogenetic protein receptor type IA; Bone morphogenetic protein receptor type IB; Bone morphogenetic protein receptor type II (BMPR-IA; BMPR-IB; BMPR-II)

Bone morphogenetic protein 2 receptors are transmembrane serine/threonine kinase receptors that bind BMP-2 and other BMP ligands to regulate numerous cell differentiation and developmental processes in vertebrates. Upon ligand (BMP-2) engagement, the receptors form heterotetramers (two type I and two type II chains), leading to phosphorylation of SMAD proteins and downstream gene expression changes critical for bone and cartilage formation, vascular development, and tissue homeostasis. Distinct disease roles are linked to gene mutations in these receptors, and abnormal signaling underlies several pathologies including cancer, pulmonary arterial hypertension, congenital bone disorders, and pediatric brain tumors. Pharmacological targeting of BMP-2 receptors (primarily their kinase activity) is a therapeutic strategy for these conditions, but carries risks such as ectopic ossification or disadvantageous signaling modulation. The term “BMP-2 receptor” is not a standardized canonical form and should be replaced with specific receptor subtypes (BMPR-IA, BMPR-IB, BMPR-II) for precision.

Other names

BMPR-IA (ALK3)BMPR-IB (ALK6)BMPR-IIActivin receptor-like kinase 3 (ALK3)Activin receptor-like kinase 6 (ALK6)

Kinase inhibition: Small molecules block receptor kinase activity, reducing aberrant BMP signaling. Ligand mimic or agonism: Recombinant BMP-2 activates the BMP pathway via these receptors.